Biomarker-driven clinical trials are a type of cancer study that uses biological markers, or biomarkers, to guide the selection of therapies. These trials aim to match patients with treatments that are more likely to be effective based on the specific characteristics of their cancer. This approach, often referred to as precision oncology, has the potential to improve treatment outcomes by tailoring therapy to the individual characteristics of each patient's cancer.

Colorectal cancer (CRC) is a significant health concern, but advancements in personalized medicine are enhancing treatment strategies and improving patient outcomes. A key component of this personalized approach is biomarker and genomic testing. Understanding these tools can empower patients and families to make informed decisions about their care.

Lung cancer remains a leading cause of cancer-related deaths worldwide. Among its various forms, non-small cell lung cancer (NSCLC) is the most prevalent, and a significant subset of these cases involve mutations in the epidermal growth factor receptor (EGFR) gene. Understanding EGFR-positive lung cancer and the evolving landscape of its treatments is crucial for patients and caregivers navigating this diagnosis.